KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.

Kohei Shitara, Sylvie Lorenzen, Jin Li, Yuxian Bai, Manuel González Fernández, Mynor Aguilar, Hirokazu Shoji, Felipe Reyes-Cosmelli, Yovany Rodriguez Peña, Luis Corrales, Lucjan Wyrwicz, Daniel Acosta Eyzaguirre, Yueyin Pan, Min-Hee Ryu, Deirdre J Cohen, Zev A Wainberg, Geoffrey Ku, Josep Tabernero, Eric Van Cutsem, Shu-Kui Qin, Do-Youn Oh, Jianming Xu, Li Wen Liang, Sonal Bordia, Pooja Bhagia, Sun Young Rha, LEAP-015 Investigators

J Clin Oncol 43(22) 2502-2514

PMID40448579
PMCIDPMC12288889
DOI10.1200/JCO-25-00748
发表日期2025-05-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adenocarcinoma. METHODS: Eligible participants 18 years and older with untreated human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastroesophageal adenocarcinoma were randomly assigned 1:1 to induction with oral lenvatinib 8 mg once daily plus pembrolizumab 400 mg intravenously once every 6 weeks (×2) and investigators' choice of capecitabine and oxaliplatin once every 3 weeks (×4) or fluorouracil, leucovorin, and oxaliplatin once every 2 weeks (×6) and consolidation with lenvatinib plus pembrolizumab, or chemotherapy. Dual primary end points were progression-free survival (PFS) and overall survival (OS) in participants with PD-L1 combined positive score (CPS) ≥1 and all participants. Secondary end points included objective response rate (ORR) and duration of response. RESULTS: Of 880 participants randomly assigned, 443 received lenvatinib plus pembrolizumab and 437 received chemotherapy. The median follow-ups were 32.2 months (range, 19.0-41.7) in participants with PD-L1 CPS ≥1 and 31.8 months (19.0-41.7) in all participants. At interim analysis, PFS was statistically significant with lenvatinib plus pembrolizumab versus chemotherapy in participants with PD-L1 CPS ≥1 (median, 7.3 v 6.9 months; hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.9]; P = .0012) and all participants (median, 7.2 v 7.0 months; HR, 0.78 [95% CI, 0.66 to 0.92]; P = .0019). The ORR was 59.5% versus 45.4% in participants with PD-L1 CPS ≥1 and 58.0% versus 43.9% in all participants, P < .0001 for both. At final analysis, OS was not statistically significant in participants with PD-L1 CPS ≥1 (median, 12.6 v 12.9 months; HR, 0.84 [95% CI, 0.71 to 1.00]; P = .0244; P value boundary = .0204). Grade ≥3 drug-related adverse event rates were 65% versus 49%. CONCLUSION: Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy provided a statistically significant improvement in PFS in advanced unresectable or metastatic gastroesophageal carcinoma at interim analysis although the clinical significance of this difference seems to be limited. No significant improvement occurred in OS in participants with PD-L1 CPS ≥1.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. PFS in participants with advanced metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma. Kaplan-Meier estimate of PFS at interim analysis in (A) participants with PD-L1 CPS ≥1 (H2; P value boundary for significance = .007000) and (B) all participants (H4; P value boundary for significance = .005999). PFS was assessed per the RECIST version 1.1 by blinded, independent central review. Tick marks represent data censored at the time of last imaging assessment. CPS, combined positive score; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; Lenva, lenvatinib; Pembro, pembrolizumab; PFS, progression-free survival.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG 2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure2 个面板

FIG 3.

FIG 3. OS in participants with advanced metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma. Kaplan-Meier estimate of OS at final analysis in (A) participants with PD-L1 CPS ≥1 (H1) and (B) all participants (H3). Tick marks represent data censored at the time of last imaging assessment. (C) Forest plot of OS at final analysis in prespecified subgroups. The unstratified Cox regression model with Efron's method of tie handling with treatment as a covariate was used to assess the magnitude of the treatment difference between arms. CAPOX, capecitabine and oxaliplatin; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; Lenva, lenvatinib; mFOLFOX6, fluorouracil, leucovorin, oxaliplatin; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NA, North America; OS, overall survival; Pembro, pembrolizumab.

A

OS

FIG 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 3. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

FIG A3.

FIG A3. DOR in participants with advanced metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma. Kaplan-Meier estimate of DOR at interim analysis. Tick marks represent data censored at the time of last imaging assessment. DOR, duration of response; HER2, human epidermal growth factor receptor 2; Lenva, lenvatinib; Pembro, pembrolizumab; ORR, objective response rate.

DOR_duration_of_response_

Duration of Response (DOR)

FIG A3. · Panel DOR_duration_of_response_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel DOR_duration_of_response_ 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. ITT, intention-to-treat.
非 KM Figure
FIG A1.FIG A1. Multiplicity strategy for α reallocation. Hypotheses (H) are indicated in order of α reallocation. CPS, combined positive score; PFS, progression-free survival; ORR, objective response rate; OS, overall survival.
非 KM Figure
FIG A2.FIG A2. Forest plot of progression-free survival at interim analysis in participants with advanced metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma. The unstratified Cox regression model with Efron's method of tie handling with treatment as a covariate was used to assess the magnitude of the treatment difference between arms. CAPOX, capecitabine and oxaliplatin; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mFOLFOX6, fluorouracil, leucovorin, and oxaliplatin; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NA, North America.
非 KM Figure